Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 575 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pediatric Cancer Patients Clear all
Terminated Phase 1 Interventional Results available

Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas

NCT03334305
View directory record Official record
Conditions
Malignant Glioma, High Grade Glioma
Interventions
TTRNA-DC vaccines with GM-CSF, Dose-intensified TMZ, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
3 Years to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 22, 2026, 2:40 PM EDT
Recruiting Phase 2 Interventional

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

NCT06847269
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Fludarabine, Cyclophosphamide, Mesna, CD19-CAR T cell Infusion
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 22, 2026, 2:40 PM EDT
Recruiting Phase 1 Interventional

Venetoclax to Augment Epigenetic Modification and Chemotherapy

NCT05317403
View directory record Official record
Conditions
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Interventions
Venetoclax, Azacitadine, Vorinostat, Cytarabine, Fludarabine, Filgrastim
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

NCT00021541
View directory record Official record
Conditions
Neurofibroma, Plexiform, Neurofibromatosis Type I
Interventions
tipifarnib, placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 25 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Jul 22, 2026, 2:40 PM EDT
Completed No phase listed Observational

Concurrent School Attendance And Cancer Therapy: The Experiences of 6-12 Year Old Pediatric Oncology Patients

NCT01383473
View directory record Official record
Conditions
Leukemia, Lymphoma, Solid Tumor
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Phase 1 Interventional Results available

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

NCT02323880
View directory record Official record
Conditions
Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, WHO Grade 3 Glioma
Interventions
Pharmacological Study, Selinexor
Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jul 22, 2026, 2:40 PM EDT
Withdrawn Phase 3 Interventional

Fever and Neutropenia in Pediatric Oncology Patients

NCT03768869
View directory record Official record
Conditions
Fever, Neutropenia
Interventions
Low Risk: Oupatient Management, Low Risk: Inpatient Management, High Risk: Inpatient Management
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
0 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Jul 22, 2026, 2:40 PM EDT
Recruiting Phase 1 Interventional

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

NCT04485559
View directory record Official record
Conditions
Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High Grade Glioma
Interventions
Everolimus, Trametinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 2:40 PM EDT
Completed No phase listed Observational

Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs

NCT03750188
View directory record Official record
Conditions
Central Nervous System Diseases, Central Nervous System Neoplasms
Interventions
ProHance
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
1 Day to 2 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Jul 22, 2026, 2:40 PM EDT
Recruiting Phase 1 Interventional

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

NCT06894979
View directory record Official record
Conditions
Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma, Childhood Glioblastoma, Childhood Malignant Glioma
Interventions
ATM Kinase Inhibitor AZD1390, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration
Drug · Procedure · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 22 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 22, 2026, 2:40 PM EDT
Terminated Phase 1 Interventional Results available

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

NCT01519323
View directory record Official record
Conditions
Malignant Melanoma
Interventions
vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Saint Petersburgh, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2016 · Synced Jul 22, 2026, 2:40 PM EDT
Completed No phase listed Observational

Pediatric EEG Monitoring

NCT04664608
View directory record Official record
Conditions
Pediatric ALL, Epilepsy
Interventions
wearable EEG sensor
Device
Lead sponsor
Northwestern University
Other
Eligibility
1 Day to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age

NCT01151410
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
17
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2016 · Synced Jul 22, 2026, 2:40 PM EDT
Recruiting Phase 1 Interventional

Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

NCT04881240
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL
Interventions
CD19-CAR(Mem) T-cells, Cyclophosphamide, Fludarabine, Mesna, CliniMACS, Leukapheresis
Biological · Drug · Device + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 22, 2026, 2:40 PM EDT
Recruiting Phase 1 Interventional

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

NCT06559189
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
CD19x22 CAR T
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Months to 30 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jul 22, 2026, 2:40 PM EDT
Recruiting Phase 1 Interventional

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

NCT06777979
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Interventions
Fludarabine, Cyclophosphamide, Mesna, CD19-CD22 CAR T cell infusion
Drug · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 22, 2026, 2:40 PM EDT
Recruiting Phase 1Phase 2 Interventional

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

NCT06625190
View directory record Official record
Conditions
Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors, Clear Cell Sarcoma, Alveolar Soft Part Sarcoma, Desmoplastic Small Round Cell Tumor, Chordoma, Rhabdoid Tumor, Epithelioid Sarcoma, Myoepithelial Tumor, Osteosarcoma, Ewing Sarcoma, Wilms Tumor
Interventions
Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
Device · Drug
Lead sponsor
University of Florida
Other
Eligibility
6 Months to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Phase 1 Interventional

Clofarabine in Adult Patients With Advanced Solid Tumors

NCT00125840
View directory record Official record
Conditions
Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric, Leukemia, Lymphocytic, Acute, Adult, Leukemia, Myelocytic, Acute, Pediatric, Leukemia, Myelocytic, Acute, Adult, Myelodysplastic Syndromes, Adult
Interventions
clofarabine (IV formulation)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Dallas, Texas • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

NCT01553149
View directory record Official record
Conditions
Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Visual Pathway Glioma
Interventions
Lenalidomide, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
113
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Jul 22, 2026, 2:40 PM EDT
Completed No phase listed Observational

Pediatric Physical Activity for Children With Cancer

NCT06012825
View directory record Official record
Conditions
Pediatric Cancer, Physical Activity
Interventions
Physical Activity
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
5 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Phase 1 Interventional

Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy

NCT00030108
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Leukemia, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ixabepilone
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
2 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jul 22, 2026, 2:40 PM EDT
Active, not recruiting Early Phase 1 Interventional

A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

NCT05386576
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Venetoclax
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

NCT03526250
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Phase 1 Interventional

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

NCT02502708
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor, Ependymoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Primary CNS Tumor
Interventions
Indoximod, Temozolomide, Conformal Radiation, Cyclophosphamide, Etoposide
Drug · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
3 Years to 21 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Aurora, Colorado • Orlando, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Jul 22, 2026, 2:40 PM EDT